Lancet Infectious Diseases最新文献

{"title":"Should science be political?","authors":"","doi":"10.1016/s1473-3099(25)00089-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00089-1","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"433 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approaches to increase access to community-based infectious disease control for ethnically, racially, and religiously marginalised populations: a scoping review","authors":"Seth W M Epling, Annika M Bjork, Lucia Martinez Cruz, Margaret C Baker","doi":"10.1016/s1473-3099(24)00744-8","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00744-8","url":null,"abstract":"Marginalised populations often have reduced access to infectious disease prevention interventions, and as a result of this and other socioeconomic factors, these populations are at a higher risk of disease. Here, we reviewed the literature of community-based interventions delivered at the individual level across multiple diseases, and focused on how to increase access to infectious disease interventions for ethnically, racially, and religiously marginalised populations. Most of the included studies only focused on a single disease and used quantitative descriptive methods. We noted the lack of research, especially in low-income and middle-income countries. Common themes on the adaptations made included the importance of trust, descriptions of how the community was engaged at a deep level, and highlighting the importance of where interventions were delivered. We conclude that there is a need for more implementation research on this topic. Understanding how to increase access is crucial for achieving universal health coverage, which is also important from a global health security perspective, especially in an era when large-scale epidemics and pandemics are becoming more common.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond mosquitoes and malaria—ivermectin in Africa","authors":"Felix Hammann, Marta F Maia","doi":"10.1016/s1473-3099(24)00835-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00835-1","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"85 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial","authors":"A Fabrice Somé, Anthony Somé, Emmanuel Sougué, Cheick Oumar W Ouédraogo, Ollo Da, S Rodrigue Dah, Frederic Nikièma, Tereza Magalhaes, Lyndsey I Gray, Will Finical, Greg Pugh, Paula Lado, Jenna C Randall, Timothy A Burton, Molly E Ring, Anna-Sophia Leon, McKenzie Colt, Fangyong Li, Kaicheng Wang, Martina Wade, Roch K Dabiré","doi":"10.1016/s1473-3099(24)00751-5","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00751-5","url":null,"abstract":"<h3>Background</h3>The success of crucial vector control efforts in Africa (eg, long-lasting insecticide-treated nets [ITNs] and indoor residual spraying) are threatened by widespread insecticide resistance and insufficient effect on outdoor mosquito biting. Studies have shown that ivermectin, used for the treatment of parasitic diseases, can kill malaria vectors that feed on the blood of treated people and thus might be an effective complementary vector control tool if administered widely to communities in malaria endemic regions. We aimed to test the safety of repeated, high-dose ivermectin mass drug administration (MDA) and its efficacy for reducing malaria incidence among children when integrated with seasonal malaria chemoprevention (SMC) delivery.<h3>Methods</h3>We conducted a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial in southwest Burkina Faso over two consecutive rainy seasons (2019–20). 14 villages or village sectors (clusters) were randomly assigned (1:1) to ivermectin or placebo MDA by random draw, and study-eligible participants (those who regularly lived in the cluster and provided written informed consent) from all households were enrolled in July, 2019 and July, 2020. Participants were eligible for MDA if they were 90 cm in height or taller and not excluded for other safety reasons (eg, pregnancy or taking SMC drugs). There were no age restrictions for participants. Each rainy season (July to October), eligible participants from the intervention group clusters received monthly high-dose oral ivermectin MDA (three daily doses, approximately 300 μg/kg dosed by height bands) and those from the control group received monthly oral placebo MDA for up to eight treatment rounds. MDA was performed by study staff alongside community health worker administration of monthly SMC to children aged 3–59 months in both groups. All participants and study personnel, apart from the pharmacist, were masked to group assignment. The primary outcome was weekly malaria incidence in children aged 10 years and younger, as assessed by weekly active case detection until week 16 of year 2, by intention to treat. Adverse events were monitored in all MDA participants through active and passive surveillance. Blood was sampled for secondary parasitological outcomes, including analysis of parasite species distribution among malaria cases. Mosquitoes were sampled from pre-selected households in three clusters per group for secondary entomological outcomes, including analysis of blood-fed mosquito survivorship, mosquito biting rates, and entomological inoculation rates. Changes in haemoglobin pre-intervention and post-intervention in children aged 10 years and younger were assessed in 2020. The trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"39 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2","authors":"Qian Wang, Ian A Mellis, Madeline Wu, Anthony Bowen, Carmen Gherasim, Riccardo Valdez, Jayesh G Shah, Lawrence J Purpura, Michael T Yin, Aubree Gordon, Yicheng Guo, David D Ho","doi":"10.1016/s1473-3099(25)00058-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00058-1","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"8 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.","authors":"Amparo L Figueroa, Dania Torres, Celia Reyes-Acuna, Paul Matherne, Anne Yeakey, Weiping Deng, Wenqin Xu, Yelena Sigal, Greer Chambers, Michelle Olsen, Bethany Girard, Jacqueline M Miller, Rituparna Das, Frances Priddy","doi":"10.1016/S1473-3099(24)00501-2","DOIUrl":"10.1016/S1473-3099(24)00501-2","url":null,"abstract":"<p><strong>Background: </strong>Most individuals show immunity to SARS-CoV-2 from vaccination or infection, or both. We aimed to determine the safety and immunogenicity of an omicron-containing COVID-19 vaccine (mRNA-1273.222) in vaccine-naive adolescents who were SARS-CoV-2 positive.</p><p><strong>Methods: </strong>Part 3 of the phase 2/3 TeenCOVE trial was a phase 3, open-label, single-arm part done in the USA and the Dominican Republic that enrolled healthy, vaccine-naive adolescents (aged 12-17 years) to receive two 50 μg doses of mRNA-1273.222 (ancestral strain Wuhan-Hu-1 and omicron subvariants BA.4 and BA.5), 6 months apart. Primary reactogenicity and safety outcomes included assessment of solicited local or systemic adverse reactions 7 days after vaccination, and unsolicited and prespecified adverse events throughout study participation. Inferred effectiveness (primary immunogenicity outcome) was established by comparing neutralising antibody responses 28 days after dose 1 of mRNA-1273.222 in SARS-CoV-2-positive adolescents with responses 28 days after dose 2 of mRNA-1273 100 μg primary series in SARS-CoV-2-negative young adults (aged 18-25 years) from the COVE trial. This study is registered with ClinicalTrials.gov (NCT04649151).</p><p><strong>Findings: </strong>Between Dec 21, 2022, and June 5, 2023, 379 adolescents (378 of whom were SARS-CoV-2 positive) received at least one mRNA-1273.222 dose and were included in the safety analysis set. The reactogenicity profile was favourable compared with the mRNA-1273 primary series, with no new safety concerns identified. Unsolicited adverse events were reported in 49 (13%) of 379 participants; no deaths or adverse events leading to study discontinuation were reported. The immunogenicity set included 245 adolescents from the per-protocol immunogenicity subset who were SARS-CoV-2 positive at baseline and 296 young adults who were SARS-CoV-2 negative. Compared with the mRNA-1273 primary series in SARS-CoV-2-negative young adults, a single dose of mRNA-1273.222 induced superior (geometric mean ratio [GMR] 95% CI lower bound >1) neutralising antibody responses against omicron BA.4 and BA.5 (GMR 48·95 [95% CI 44·21-54·21]) and non-inferior (GMR 95% CI lower bound >0·667) neutralising antibody responses against ancestral SARS-CoV-2 (GMR 4·25 [95% CI 3·69-4·88]) in SARS-CoV-2-positive adolescents.</p><p><strong>Interpretation: </strong>In vaccine-naive, SARS-CoV-2-positive adolescents, single-dose mRNA-1273.222 was effective against COVID-19 based on successful immunobridging to the two-dose mRNA-1273 primary series in young adults. The findings support a simplified single-dose vaccination schedule with variant-containing mRNA vaccines, regardless of previous vaccination status.</p><p><strong>Funding: </strong>Moderna.</p>","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"208-217"},"PeriodicalIF":36.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 immunisation strategies for adolescents.","authors":"Wei-Xiao Wang, Feng-Cai Zhu","doi":"10.1016/S1473-3099(24)00563-2","DOIUrl":"10.1016/S1473-3099(24)00563-2","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"143-144"},"PeriodicalIF":36.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Difficulties in diagnosing tuberculosis infection in childhood.","authors":"Anna Starshinova","doi":"10.1016/S1473-3099(24)00569-3","DOIUrl":"10.1016/S1473-3099(24)00569-3","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"140-141"},"PeriodicalIF":36.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before-after control-intervention paired-series trial.","authors":"Fernando Abad-Franch, José Joaquín Carvajal-Cortés, Ana Carolina Lemos Rabelo, Eduardo Viana Vieira Gusmão, Samylla Suany de Souza Soares, Sérgio Luiz Bessa Luz","doi":"10.1016/S1473-3099(24)00492-4","DOIUrl":"10.1016/S1473-3099(24)00492-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Mosquitoes transmit important human pathogens, including dengue virus, but are notoriously hard to control. Mosquito-disseminated pyriproxyfen (MDPPF) uses the mosquitoes themselves to transfer particles of pyriproxyfen, a potent larvicide and pupicide, from lure dissemination stations to untreated larval habitats. MDPPF can reduce mosquito densities, but possible epidemiological effects remain to be measured. We aimed to investigate whether MDPPF can help curb mosquito-borne disease transmission.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this pragmatic, before-after control-intervention paired-series (BACIPS) trial conducted in Belo Horizonte, Brazil, municipal vector-control staff deployed, then serviced monthly (from November, 2017, to December, 2019), 2481 pyriproxyfen dissemination stations in a nine-neighbourhood cluster with a history of high dengue endemicity; nine adjacent neighbourhoods were designated as a buffer area, and the remaining 258 city neighbourhoods as the control area. The primary epidemiological outcome of the trial was dengue incidence. Based on official dengue-notification records broken down by week and neighbourhood (ie, week-neighbourhood case counts; N=265 162 cases in total) from Jan 1, 2016, to Dec 31, 2019, we estimated intervention effects on incidence using a BACIPS approach and negative-binomial generalised linear mixed models (GLMMs). Zika and chikungunya cases were too rare to be assessed with confidence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Week-neighbourhood dengue incidence ranged from 0 to 379·5 cases per 10 000 residents, with epidemic outbreaks recorded in 2016 and 2019. Intention-to-treat, BACIPS-GLMM adjusted estimates indicate that MDPPF deployment was associated with a net 29% (95% CI 21-36; p=4·7 × 10&lt;sup&gt;-10&lt;/sup&gt;) average decrease of dengue incidence in intervention neighbourhoods and a net 21% (12-30; p=2·7 × 10&lt;sup&gt;-5&lt;/sup&gt;) average decrease in buffer neighbourhoods. In contrast, and due in part to larger uncertainties, average incidence rates were statistically indistinguishable across areas before the intervention (intervention area p=0·47; buffer area p=0·11) and across trial periods in control neighbourhoods (p=0·74). Hence, in the all-too-common scenario of a 100 000-case outbreak, public health managers could expect MDPPF to reduce the strain on the health-care system by at least about 29 000 (21 000-36 000) symptomatic cases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;Our results suggest that MDPPF can help prevent dengue under the many operational constraints of real-world vector-control interventions and despite incomplete coverage and potential dilution of intervention effects. MDPPF holds promise as an additional tool for dengue control.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Funding: &lt;/strong&gt;Coordenação-Geral de Vigilância de Arboviroses, Secretaria de Vigilância em Saúde e Ambiente, Ministry of Health, Brazil, Secretaria Municipal de Saúde de Belo Horizonte, Brazil, and Fundação de Amparo","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"176-187"},"PeriodicalIF":36.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant","authors":"Mehul S Suthar, Kelly E Manning, Madison L Ellis, Shilpi Jain, Kareem Bechnak, Jake Vander Velden, Farida Laboune, Amy R Henry, Sucheta Godbole, Sungjin Kim, Malaya K Sahoo, Isabel Paredes, Serena M Dib, Suha Kalash, Christelle Radi, Heather Hicks, Azaibi Tamin, Meredith Gardner, Nicole Bowen, Peter Cook, Alberto Moreno","doi":"10.1016/s1473-3099(25)00007-6","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00007-6","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"20 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143072490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}